102 related articles for article (PubMed ID: 11087639)
1. Clinical outcome and bromodeoxyuridine-derived proliferation indices in 75 invasive breast carcinomas.
Cutress RI; Mullee MA; Royle GT; Rew DA
Eur J Surg Oncol; 2000 Dec; 26(8):747-50. PubMed ID: 11087639
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment proliferation parameters do not add predictive power to clinical factors in cervical cancer treated with definitive radiation therapy.
Tsang RW; Juvet S; Pintilie M; Hill RP; Wong CS; Milosevic M; Chapman W; Levin W; Manchul LA; Fykes AW
Clin Cancer Res; 2003 Oct; 9(12):4387-95. PubMed ID: 14555510
[TBL] [Abstract][Full Text] [Related]
3. Changes in management techniques and patterns of disease recurrence over time in patients with breast carcinoma treated with breast-conserving therapy at a single institution.
Pass H; Vicini FA; Kestin LL; Goldstein NS; Decker D; Pettinga J; Ingold J; Benitez P; Neumann K; Rebner M; Dekhne N; Martinez A
Cancer; 2004 Aug; 101(4):713-20. PubMed ID: 15305400
[TBL] [Abstract][Full Text] [Related]
4. Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: analysis of a series of 271 patients with stage I and II breast cancer.
Moureau-Zabotto L; Bouchet C; Cesari D; Uzan S; Lefranc JP; Antoine M; Genestie C; Deniaud-Alexandre E; Bernaudin JF; Touboul E; Fleury-Feith J
Breast Cancer Res Treat; 2005 May; 91(1):61-71. PubMed ID: 15868432
[TBL] [Abstract][Full Text] [Related]
5. [Breast-conserving treatment for early invasive lobular breast cancer: 15 years results].
Fodor J; Sulyok Z; Polgár C; Major T; Tóth J; Németh G
Magy Seb; 2001 Aug; 54(4):209-14. PubMed ID: 11550486
[TBL] [Abstract][Full Text] [Related]
6. Final report on the University of California-San Francisco experience with bromodeoxyuridine labeling index as a prognostic factor for the survival of glioma patients.
Lamborn KR; Prados MD; Kaplan SB; Davis RL
Cancer; 1999 Feb; 85(4):925-35. PubMed ID: 10091772
[TBL] [Abstract][Full Text] [Related]
7. Analysis of correlation between mitotic index, MIB1 score and S-phase fraction as proliferation markers in invasive breast carcinoma. Methodological aspects and prognostic value in a series of 257 cases.
Caly M; Genin P; Ghuzlan A A; Elie C; Fréneaux P; Klijanienko J; Rosty C; Sigal-Zafrani B; Vincent-Salomon A; Douggaz A; Zidane M; Sastre-Garau X
Anticancer Res; 2004; 24(5B):3283-8. PubMed ID: 15510624
[TBL] [Abstract][Full Text] [Related]
8. The labelling index of human and mouse tumours assessed by bromodeoxyuridine staining in vitro and in vivo and flow cytometry.
Wilson GD; McNally NJ; Dunphy E; Kärcher H; Pfragner R
Cytometry; 1985 Nov; 6(6):641-7. PubMed ID: 4064843
[TBL] [Abstract][Full Text] [Related]
9. Sentinel lymph node biopsy alone has no adverse impact on the survival of patients with breast cancer.
Takei H; Suemasu K; Kurosumi M; Horii Y; Ninomiya J; Yoshida M; Hagiwara Y; Inoue K; Tabei T
Breast J; 2006; 12(5 Suppl 2):S157-64. PubMed ID: 16958996
[TBL] [Abstract][Full Text] [Related]
10. S-phase fraction determined on fine needle aspirates is an independent prognostic factor in breast cancer - a multivariate study of 770 patients.
Gazic B; Pizem J; Bracko M; Cufer T; Borstnar S; Pohar-Marinsek Z; Us-Krasovec M
Cytopathology; 2008 Oct; 19(5):294-302. PubMed ID: 18070112
[TBL] [Abstract][Full Text] [Related]
11. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
12. Cell proliferation in ovarian carcinoma: superior accuracy of S-phase fraction (SPF) by DNA labeling index versus flow cytometric SPF, lack of independent prognostic power for SPF and DNA ploidy, and limited effect of SPF on tumor growth rate.
Meyer JS; Gersell DJ; Yim S
Gynecol Oncol; 2001 Jun; 81(3):466-76. PubMed ID: 11371140
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometry and quantitative immunohistochemical study of cell cycle regulation proteins in invasive breast carcinoma: prognostic significance.
Michels JJ; Duigou F; Marnay J; Henry-Amar M; Delozier T; Denoux Y; Chasle J
Cancer; 2003 Mar; 97(6):1376-86. PubMed ID: 12627500
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of the correlations of cell proliferation activity with lymphatic and vascular invasion and prognosis in gastric carcinoma].
Wu YF; Xu HM; Chen JQ
Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):492-5. PubMed ID: 16188150
[TBL] [Abstract][Full Text] [Related]
15. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
16. Relations of proliferative activities of gastric carcinoma cells to lymphatic involvement, venous invasion and prognosis.
Wu YF; Xu HM; Chen JQ
Chin Med J (Engl); 2004 Oct; 117(10):1530-5. PubMed ID: 15498378
[TBL] [Abstract][Full Text] [Related]
17. Initially metastatic breast carcinoma has a distinct disease pattern but an equivalent outcome compared with recurrent metastatic breast carcinoma.
Jimeno A; Amador ML; González-Cortijo L; Tornamira MV; Ropero S; Valentín V; Hornedo J; Cortés-Funes H; Colomer R
Cancer; 2004 May; 100(9):1833-42. PubMed ID: 15112263
[TBL] [Abstract][Full Text] [Related]
18. In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor.
Janssen EA; Baak JP; Guervós MA; van Diest PJ; Jiwa M; Hermsen MA
J Pathol; 2003 Dec; 201(4):555-61. PubMed ID: 14648658
[TBL] [Abstract][Full Text] [Related]
19. Proliferative activity in primary breast carcinomas is a salient prognostic factor.
Michels JJ; Marnay J; Delozier T; Denoux Y; Chasle J
Cancer; 2004 Feb; 100(3):455-64. PubMed ID: 14745860
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome and bromodeoxyuridine derived proliferation indices in 100 colonic and rectal carcinomas.
Cutress RI; Mullee MA; Rew DA
Eur J Surg Oncol; 2002 Aug; 28(5):516-9. PubMed ID: 12217304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
